enrasentan

decreases ischemic brain injury; an endothelin A and B receptor antagonist; structure in first source

Also Known As:

(1S,2R,3S)-3-(2-(2-Hydroxyethoxy)-4-methoxyphenyl)-1-(3,4- (methylenedioxy)phenyl)-5-propoxy-2-indancarboxylic acid; 3-(2-(2-hydroxyeth-1-yloxy)-4-methoxyphenyl)-1-(3,4-methylenedioxyphenyl)-5-(prop-1-yloxy)indan-2-carboxylic acid; SB 217242; SB-217242

Networked: 14 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Cosenzi, Alessandro: 2 articles (01/2003 - 04/2002)
2.	Bayes, M: 1 article (12/2006)
3.	Prous, J R: 1 article (12/2006)
4.	Rabasseda, X: 1 article (12/2006)
5.	Barlow, M M: 1 article (06/2006)
6.	Cleland, J G F: 1 article (06/2006)
7.	Dargie, H J: 1 article (06/2006)
8.	Groenning, B A: 1 article (06/2006)
9.	Grothues, F: 1 article (06/2006)
10.	Pennell, D J: 1 article (06/2006)

Related Diseases

1.	Neointima 06/09/1998 - "With the use of serial MRI and histologic measurements, it is demonstrated that protection from both lumen volume reduction and neointima formation is obtained in this model by use of a potent, nonpeptide dual ET(A)/ET(B) receptor antagonist, SB 217242. " 06/09/1998 - "Application of serial in vivo magnetic resonance imaging to evaluate the efficacy of endothelin receptor antagonist SB 217242 in the rat carotid artery model of neointima formation."
2.	Hypoxia (Hypoxemia) 11/01/1999 - "Ten minutes before hypoxemia, the Hyp group (n = 10) was given saline and the 1-mg (n = 9) and 5-mg group (n = 9), respectively, were given 1 and 5 mg/kg i.v. SB 217242 (an ET receptor antagonist). " 01/01/1999 - "SB 217242 (3.6 or 10.8 mg/day, ip) markedly reduced (80 and 95%, respectively) hypoxia-induced increases in pulmonary artery pressure. " 01/01/1999 - "There was no difference in the sensitivity to ET-1 or the potency of SB 217242 in pulmonary artery from normoxic rats vs. rats exposed to hypoxia (9% O2) for 14 days. " 01/01/1999 - "Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat." 12/01/1997 - "SB 217242, administered by continuous intraperitoneal infusion via mini osmotic pump (0.36, 3.6 or 10.8 mg/day), significantly reduced (by about 50%) hypoxia-induced pulmonary artery pressure increases at all three doses used. "
3.	Pulmonary Hypertension 12/01/1997 - "The results of the present study provide further preclinical evidence for a pathophysiological role of ET-1 and the potential therapeutic utility of ET receptor antagonists, such as SB 217242, in pulmonary hypertension." 01/01/1999 - "The inhibitory effects of SB 217242 on the functional and remodeling changes induced by hypoxia provide further evidence that ET may play a central role in pulmonary hypertension and that ET receptor antagonists may have a utility in the treatment of this disease." 01/01/1998 - "The inhibitory influence of SB 217242 on the functional and morphologic changes induced by hypoxia provides further evidence for a role for ET and the potential utility of ET receptor antagonists in the treatment of pulmonary hypertension." 12/01/1997 - "This study investigated the effects of the nonpeptide endothelin (ET) receptor antagonist, SB 217242, against ET-1-induced pulmonary pressor responses and in a model of hypoxia-induced pulmonary hypertension in the guinea pig. "
4.	Stroke (Strokes) 01/01/1995 - "The fact that a 30% reduction in ischemic brain injury can be demonstrated after oral administration of SB 217242 suggests that ET antagonists may be of therapeutic utility in focal stroke." 10/01/2001 - "In the current study, the effects of an orally active mixed endothelin-A/endothelin-B (ETA /ETB ) receptor antagonist (enrasentan) were assessed in a model of cardiac hypertrophy and dysfunction (spontaneously hypertensive stroke prone rats) maintained on a high-salt/high-fat diet. "
5.	Hypertension (High Blood Pressure) 04/01/2002 - "The aim of this study was to evaluate whether enrasentan could reverse the hypertension and reduce the target organ damage induced by an HFD. " 01/01/2003 - "In rats with hyperinsulinemia and hypertension enrasentan normalized blood pressure and prevented cardiac and renal damage. " 04/01/2002 - "Antihypertensive treatment with enrasentan (SB217242) in an animal model of hypertension and hyperinsulinemia."

Related Drugs and Biologics

1.	Endothelin Receptor Antagonists
2.	Endothelins (Endothelin)
3.	Endothelin Receptors (Endothelin Receptor)
4.	Salts
5.	Enalapril
6.	(1S,2R,3S)- 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)- 4- methoxyphenyl)- 2,3- dihydro- 5- propoxy- 1H-Indene-2-carboxylic acid
7.	Ghrelin
8.	Papillomavirus Vaccines (HPV Vaccines)
9.	Measles-Mumps-Rubella Vaccine (MMR Vaccine)
10.	Yellow Fever Vaccine (Vaccine, Yellow Fever)

Related Therapies and Procedures

1.	Intravenous Administration
2.	Stents
3.	Parenteral Infusions
4.	Oral Administration